MA46524A - Composés de biphényl-sulfonamide destinés au traitement de néphropathies - Google Patents

Composés de biphényl-sulfonamide destinés au traitement de néphropathies

Info

Publication number
MA46524A
MA46524A MA046524A MA46524A MA46524A MA 46524 A MA46524 A MA 46524A MA 046524 A MA046524 A MA 046524A MA 46524 A MA46524 A MA 46524A MA 46524 A MA46524 A MA 46524A
Authority
MA
Morocco
Prior art keywords
nephropathies
biphenyl
treatment
sulfonamide compounds
sulfonamide
Prior art date
Application number
MA046524A
Other languages
English (en)
French (fr)
Inventor
Radko Komers
Alvin Shih
Original Assignee
Retrophin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retrophin Inc filed Critical Retrophin Inc
Publication of MA46524A publication Critical patent/MA46524A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA046524A 2016-10-13 2017-10-13 Composés de biphényl-sulfonamide destinés au traitement de néphropathies MA46524A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662407860P 2016-10-13 2016-10-13
US201662423079P 2016-11-16 2016-11-16

Publications (1)

Publication Number Publication Date
MA46524A true MA46524A (fr) 2019-08-21

Family

ID=60191503

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046524A MA46524A (fr) 2016-10-13 2017-10-13 Composés de biphényl-sulfonamide destinés au traitement de néphropathies

Country Status (10)

Country Link
US (5) US20190262317A1 (OSRAM)
EP (1) EP3525784A1 (OSRAM)
JP (4) JP2019530713A (OSRAM)
KR (4) KR20190077348A (OSRAM)
CN (5) CN114788823A (OSRAM)
AU (3) AU2017341825B2 (OSRAM)
BR (1) BR112019007576A2 (OSRAM)
CA (1) CA3039819A1 (OSRAM)
MA (1) MA46524A (OSRAM)
WO (1) WO2018071784A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7524167B2 (ja) * 2018-10-04 2024-07-29 トラビア セラピューティクス, インコーポレイテッド Iv型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
CN114126712A (zh) * 2018-12-21 2022-03-01 特拉维尔治疗公司 无定形司巴森坦(sparsentan)组合物
US20220304979A1 (en) * 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
IL293921A (en) 2019-12-17 2022-08-01 Chinook Therapeutics Inc Methods for treating iga kidney disease with atresantan
JP2023521169A (ja) * 2020-04-10 2023-05-23 チヌーク セラピューティクス,インコーポレイテッド 糖尿病性腎疾患の処置方法
WO2022246200A1 (en) 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Methods of treating kidney diseases or disorders
KR20240051999A (ko) 2021-08-26 2024-04-22 상하이 한서 바이오메디컬 컴퍼니 리미티드 방향족 고리 함유 생물학적 길항제, 이의 제조 방법 및 용도
AR128112A1 (es) * 2021-12-28 2024-03-27 Alchemedicine Inc Compuesto, antagonista del receptor de angiotensina ii tipo 1 y composición farmacéutica
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンa受容体拮抗剤、アンジオテンシンiiタイプ1受容体拮抗剤及び医薬組成物
WO2024249509A1 (en) 2023-05-31 2024-12-05 Travere Therapeutics, Inc. Sparsentan for use in a method of treating iga-mediated diseases
WO2025064688A1 (en) 2023-09-20 2025-03-27 Travere Therapeutics, Inc. Sparsentan for treating immunoglobulin a nephropathy (igan)
CN118666826A (zh) * 2024-08-23 2024-09-20 成都臻拓医药科技有限公司 一种司帕生坦原料药的重结晶纯化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
KR20010083092A (ko) 1998-07-06 2001-08-31 스티븐 비. 데이비스 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드
EP1237888B1 (en) 1999-12-15 2006-09-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
EP2413930A4 (en) * 2009-03-31 2012-09-26 Ligand Pharm Inc ORAL FORMULATION OF ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS BASED ON DIPHENYLSULFONAMIDE TO TREAT HIGH BLOOD PRESSURE AND DIABETIC NEPHROPATHY
WO2010135350A2 (en) 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
US9719981B2 (en) * 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
LT3126330T (lt) * 2014-04-04 2019-04-25 Pfizer Inc. Bicikliniai kondensuoti heteroarilo arba arilo junginiai, ir jų panaudojimas kaip irak4 inhibitorių
JP7524167B2 (ja) 2018-10-04 2024-07-29 トラビア セラピューティクス, インコーポレイテッド Iv型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物

Also Published As

Publication number Publication date
KR20190077348A (ko) 2019-07-03
US20210196688A1 (en) 2021-07-01
US20200281901A1 (en) 2020-09-10
US20250325523A1 (en) 2025-10-23
AU2017341825B2 (en) 2023-06-01
CN116983302A (zh) 2023-11-03
AU2023219839A1 (en) 2023-09-07
CA3039819A1 (en) 2018-04-19
JP2022141802A (ja) 2022-09-29
KR20220132030A (ko) 2022-09-29
EP3525784A1 (en) 2019-08-21
JP2025060754A (ja) 2025-04-10
JP2022137245A (ja) 2022-09-21
AU2023219839B2 (en) 2025-08-21
CN117017985A (zh) 2023-11-10
US20250325522A1 (en) 2025-10-23
JP2019530713A (ja) 2019-10-24
AU2017341825A1 (en) 2019-04-11
KR20230066644A (ko) 2023-05-16
US20190262317A1 (en) 2019-08-29
BR112019007576A2 (pt) 2019-07-02
KR102528435B1 (ko) 2023-05-03
CN117085013A (zh) 2023-11-21
WO2018071784A1 (en) 2018-04-19
AU2025271121A1 (en) 2025-12-18
KR20240162167A (ko) 2024-11-14
CN114788823A (zh) 2022-07-26
US10864197B2 (en) 2020-12-15
CN110049764A (zh) 2019-07-23

Similar Documents

Publication Publication Date Title
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
EP3691623A4 (en) BENZOSULFONYL COMPOUNDS
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3720430A4 (en) BENZOCARBONYL COMPOUNDS
MA45192A (fr) Traitement d'association
EP3370721A4 (en) TREATMENT OF OSTEOARTHRITIS
EP3388004A4 (en) Treatment instrument
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
EP3340971A4 (en) METHOD FOR TREATING LENNOX-GASTAUT SYNDROME WITH FENFLURAMINE
EP3445750A4 (en) THERAPEUTIC COMPOUNDS
EP3409744A4 (en) SURFACE TREATMENT AGENT
EP3852745A4 (en) COMPOUNDS FOR TREATMENT OF CERTAIN LEUKEMIA
EP3362065A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES
MA47820A (fr) Traitement de la glycogénose de type iii
EP3406336A4 (en) NANO FOIL OF CORE CASE STRUCTURE TYPE
EP3431566A4 (en) SURFACE TREATMENT AGENT
EP3016944A4 (en) COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS
EP3464336A4 (en) LINKS
IL282114A (en) Processes for preparing functionalized cyclooctenes
EP3371151A4 (en) COMPOUNDS FOR THE TREATMENT OF CANCER AND EPIGENETICS
EP3349793A4 (en) ANTI-S100A8 FOR THE TREATMENT OF LEUKEMIA
EP3416645A4 (en) COMPOUNDS FOR THE TREATMENT OF MALARIA
EP3007722A4 (en) METHOD FOR THE TREATMENT OF HYPOTONIA
EP3270968C0 (fr) Nouvelles compositions antivirales pour le traitement de la grippe
MA45552A (fr) Compositions destinées au traitement de l'amylose